Cargando…

Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets

PURPOSE: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschos, Marilita M, Moustafa, Giannis A, Papakonstantinou, Vasiliki D, Tsatsos, Michael, Laios, Konstantinos, Antonopoulou, Smaragdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402915/
https://www.ncbi.nlm.nih.gov/pubmed/28458520
http://dx.doi.org/10.2147/DDDT.S131582
_version_ 1783231323274477568
author Moschos, Marilita M
Moustafa, Giannis A
Papakonstantinou, Vasiliki D
Tsatsos, Michael
Laios, Konstantinos
Antonopoulou, Smaragdi
author_facet Moschos, Marilita M
Moustafa, Giannis A
Papakonstantinou, Vasiliki D
Tsatsos, Michael
Laios, Konstantinos
Antonopoulou, Smaragdi
author_sort Moschos, Marilita M
collection PubMed
description PURPOSE: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action. MATERIALS AND METHODS: The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]). RESULTS: Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP- and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (P<0.05). CONCLUSION: This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets.
format Online
Article
Text
id pubmed-5402915
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54029152017-04-28 Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets Moschos, Marilita M Moustafa, Giannis A Papakonstantinou, Vasiliki D Tsatsos, Michael Laios, Konstantinos Antonopoulou, Smaragdi Drug Des Devel Ther Original Research PURPOSE: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action. MATERIALS AND METHODS: The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]). RESULTS: Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP- and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (P<0.05). CONCLUSION: This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets. Dove Medical Press 2017-04-19 /pmc/articles/PMC5402915/ /pubmed/28458520 http://dx.doi.org/10.2147/DDDT.S131582 Text en © 2017 Moschos et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed
spellingShingle Original Research
Moschos, Marilita M
Moustafa, Giannis A
Papakonstantinou, Vasiliki D
Tsatsos, Michael
Laios, Konstantinos
Antonopoulou, Smaragdi
Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title_full Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title_fullStr Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title_full_unstemmed Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title_short Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
title_sort anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402915/
https://www.ncbi.nlm.nih.gov/pubmed/28458520
http://dx.doi.org/10.2147/DDDT.S131582
work_keys_str_mv AT moschosmarilitam antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets
AT moustafagiannisa antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets
AT papakonstantinouvasilikid antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets
AT tsatsosmichael antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets
AT laioskonstantinos antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets
AT antonopoulousmaragdi antiplateleteffectsofantiglaucomatouseyedropsaninvitrostudyonhumanplatelets